Profile

Jianfeng Xu, M.D., Dr. P.H.Wake Forest School of Medicine

Education & Training

  • M.D., Shanghai Medical University-China , 1984
  • M.Sc., Shanghai Medical University-China , 1987
  • M.P.H., Johns Hopkins University School of Public Health , 1992
  • Dr.P.H., Johns Hopkins University School of Public Health , 1997

Memberships

  • Am Soc Of Human Genetics
Jianfeng Xu, M.D., Dr. P.H.

Jianfeng Xu, M.D., Dr. P.H.

Associate Director, Center for Genomics and Personalized Medicine Research
Director, Center for Cancer Genomics
Professor, Center for Genomics and Personalized Medicine Research
Center for Genomics and Personalized Medicine Research
Comprehensive Cancer Center
Center for Cancer Genomics
Cancer Biology
Epidemiology & Prevention
Urology
Translational Science Institute

Research Interests

cancer/oncogenesis, epidemiology, genetics/genome, health services, research/outc

Contact Information

Academic: 336-716-6253 | Department: 336-713-7500

Email: jxu@wakehealth.edu

Recent Publications

Karlsson R, Aly M, Clements M, Zheng L, Adolfsson J, Xu J, Gronberg H, Wiklund F. A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. Eur Urol. 2014;65(1):169-176.

He M, Wu C, Xu J, Guo H, Yang H, Zhang X, Sun J, Yu D, Zhou L, Peng T, He Y, Gao Y, Yuan J, Deng Q, Dai X, Tan A, Feng Y, Zhang H, Min X, Yang X, Zhu J, Zhai K, Chang J, Qin X, Tan W, Hu Y, Lang M, Tao S, Li Y, Li Y, Feng J, Li D, Kim ST,. A genome wide association study of genetic loci that influence tumour biomarkers cancer antigen 19-9, carcinoembryonic antigen and a fetoprotein and their associations with cancer risk. Gut. 2014;63(1):143-151.


Saunders EJ, Dadaev T, Leongamornlert DA, Jugurnauth-Little S, Tymrakiewicz M, Wiklund F, Al Olama AA, Benlloch S, Neal DE, Hamdy FC, Donovan JL, Giles GG, Severi G, Gronberg H, Aly M, Haiman CA, Schumacher F, Henderson BE, Lindstrom S, Kraft P,. Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer. PLoS Genet. 2014;10(2):e1004129.


Teerlink CC, Thibodeau SN, McDonnell SK, Schaid DJ, Rinckleb A, Maier C, Vogel W, Cancel-Tassin G, Egrot C, Cussenot O, Foulkes WD, Giles GG, Hopper JL, Severi G, Eeles R, Easton D, Kote-Jarai Z, Guy M, Cooney KA, Ray AM, Zuhlke KA, Lange EM,. Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. Hum Genet. 2014;133(3):347-356.

Lange EM, Johnson AM, Wang Y, Zuhlke KA, Lu Y, Ribado JV, Keele GR, Li J, Duan Q, Li G, Gao Z, Li Y, Xu J, Isaacs WB, Zheng S, Cooney KA. Genome-wide association scan for variants associated with early-onset prostate cancer. PLoS One. 2014;9(4):e93436.

Pan L, Zhang L, Zhang W, Wu X, Li Y, Yan B, Zhu X, Liu X, Yang C, Xu J, Zhou G, Xu A, Li H, Liu Y. A genome-wide association study identifies polymorphisms in the HLA-DR region associated with non-response to hepatitis B vaccination in Chinese Han populations. Hum Mol Genet. 2014;23(8):2210-2219.

Xiong ZQ, Yu HJ, Ding Y, Feng CC, Wei HM, Tao S, Huang D, Zheng SL, Sun JL, Xu JF, Fang ZJ. RNA sequencing reveals upregulation of RUNX1-RUNX1T1 gene signatures in clear cell renal cell carcinoma. Biomed Res Int. 2014;():450621.


Ho GY, Wang T, Zheng SL, Tinker L, Xu J, Rohan TE, Wassertheil-Smoller S, Xue X, Augenlicht LH, Peters U, Phipps AI, Strickler HD, Gunter MJ, Cushman M. Circulating soluble cytokine receptors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2014;23(1):179-188.

Liang Y, Tang W, Huang T, Gao Y, Tan A, Yang X, Zhang H, Hu Y, Qin X, Li S, Zhang S, Mo L, Liang Z, Shi D, Huang Z, Guan Y, Zhou J, Winkler C, O'Brien SJ, Xu J, Mo Z, Peng T. Genetic variations affecting serum carcinoembryonic antigen levels and status of regional lymph nodes in patients with sporadic colorectal cancer from Southern China. PLoS One. 2014;9(6):e97923.

Wang W, Wang M, Wang L, Adams TS, Tian Y, Xu J. Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis. Sci Rep. 2014;4():5012.

Wu YS, Na R, Xu JF, Bai PD, Jiang HW, Ding Q. The influence of prostate volume on cancer detection in the Chinese population. Asian J Androl. 2014;16(3):482-486.

Amin Al Olama A, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, Benlloch S, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Hunter DJ, Henderson BE, Thun MJ, Gaziano M, Giovannucci EL, Siddiq A, Travis RC,. A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet. 2013;22(2):408-415.

Jiang DK, Sun J, Cao G, Liu Y, Lin D, Gao YZ, Ren WH, Long XD, Zhang H, Ma XP, Wang Z, Jiang W, Chen TY, Gao Y, Sun LD, Long JR, Huang HX, Wang D, Yu H, Zhang P, Tang LS, Peng B, Cai H, Liu TT, Zhou P, Liu F, Lin X,. Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet. 2013;45(1):72-75.

Jin G, Zheng SL, Lilja H, Kim ST, Tao S, Gao Z, Young T, Wiklund F, Feng J, Isaacs WB, Rittmaster RS, Gronberg H, Condreay LD, Sun J, Xu J. Genome-wide association study identifies loci at ATF7IP and KLK2 associated with percentage of circulating free PSA. Neoplasia. 2013;15(1):95-101.

Lin X, Qu L, Chen Z, Xu C, Ye D, Shao Q, Wang X, Qi J, Chen Z, Zhou F, Wang M, Wang Z, He D, Wu D, Gao X, Yuan J, Wang G, Xu Y, Wang G, Dong P, Jiao Y, Yang J, Ou-Yang J, Jiang H,Turner AR, Tao S, Na R, Ding Q, Lu D, Shi R, et al. A novel germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men. Prostate. 2013;73(2):169-175.

Xu J, Lange EM, Lu L, Zheng SL, Wang Z, Thibodeau SN, Cannon-Albright LA, Teerlink CC, Camp NJ, Johnson AM, Zuhlke KA, Stanford JL, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Maier C, Luedeke M, Vogel W, Schleutker J,. HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet. 2013;132(1):5-14.

Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, Esopi D, Irizarry RA, Getzenberg RH, Nelson WG, Luo J, Xu J, Isaacs WB, Bova GS, Yegnasubramanian S. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med. 2013;5(169):169ra10.

Lindberg J, Klevebring D, Liu W, Neiman M, Xu J, Wiklund P, Wiklund F, Mills IG, Egevad L, Gronberg H. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur Urol. 2013;63(2):347-353.

Palmer NR, Tooze JA, Turner AR, Xu J, Avis NE. African American prostate cancer survivors' treatment decision-making and quality of life. Patient Educ Couns. 2013;90(1):61-68.

Sun J, Na R, Hsu FC, Zheng SL, Wiklund F, Condreay LD, Trent JM, Xu J. Genetic score is an objective and better measurement of inherited risk of prostate cancer than family history [letter]. Eur Urol. 2013;63(3):585-587.

Hong MG, Karlsson R, Magnusson PK, Lewis MR, Isaacs W, Zheng LS [sic] [Zheng SL], Xu J, Gronberg H, Ingelsson E, Pawitan Y, Broeckling C, Prenni JE, Wiklund F, Prince JA. A genome-wide assessment of variability in human serum metabolism. Hum Mutat. 2013;34(3):515-524.

Chen Z, Sun J, Kim ST, Groskopf J, Feng J, Isaacs WB, Rittmaster RS, Condreay LD, Zheng SL, Xu J. Genome-wide association study identifies genetic determinants of urine PCA3 levels in men. Neoplasia. 2013;15(4):448-453.


Sun J, Tao S, Gao Y, Peng T, Tan A, Zhang H, Yang X, Qin X, Hu Y, Feng J, Kim ST, Lin X, Wu Y, Zhang J, Li Z, Li L, Mo L, Liang Z, Shi D, Huang Z, Huang X, Liu M, Liu Q, Zhang S, Lilly Zheng S, Xu J, Mo Z. Genome-wide association study identified novel genetic variant on SLC45A3 gene associated with serum levels prostate-specific antigen (PSA) in a Chinese population. Hum Genet. 2013;132(4):423-429.

Xu J, Sun J, Zheng SL. Prostate cancer risk-associated genetic markers and their potential clinical utility. Asian J Androl. 2013;15(3):314-322.

Chen Z, Greenwood C, Isaacs WB, Foulkes WD, Sun J, Zheng SL, Condreay LD, Xu J. The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: results from the REDUCE trial. Carcinogenesis. 2013;34(6):1260-1264.

Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F,. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet. 2013;45(4):385-391.

Jiao Y, Wang L, Gu X, Tao S, Tian L, Na R, Chen Z, Kang J, Zheng SL, Xu J, Sun J, Qi J. LILRA3 is associated with benign prostatic hyperplasia risk in a Chinese population. Int J Mol Sci. 2013;14(5):8832-8840.

Wu H, Qian J, Xu J, Sun A, Sun W, Wang Q, Ge J. Besides CYP2C19, PON1 genetic variant influences post-clopidogrel platelet reactivity in Chinese patients [letter]. Int J Cardiol. 2013;165(1):204-206.

Li HF, Ni W, Xiong ZQ, Xu J, Wu ZY. PRRT2 c.649dupC mutation derived from de novo in paroxysmal kinesigenic dyskinesia. CNS Neurosci Ther. 2013;19(1):61-65.

Li HF, Chen WJ, Ni W, Wang KY, Liu GL, Wang N, Xiong ZQ, Xu J, Wu ZY. PRRT2 mutation correlated with phenotype of paroxysmal kinesigenic dyskinesia and drug response. Neurology. 2013;80(16):1534-1535.

Qi J, Tian L, Chen Z, Wang L, Tao S, Gu X, Na R, Jiao Y, Kang J, Zheng S, Xu J, Sun J. Genetic variants in 2q31 and 5p15 are associated with aggressive benign prostatic hyperplasia in a Chinese population. Prostate. 2013;73(11):1182-1190.

Liu W, Xie CC, Thomas CY, Kim ST, Lindberg J, Egevad L, Wang Z, Zhang Z, Sun J, Sun J, Koty PP, Kader AK, Cramer SD, Bova GS, Zheng SL, Gronberg H, Isaacs WB, Xu J. Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer. 2013;119(13):2405-2412.

Ding G, Wang L, Xu H, Xu Z, Feng C, Ding Q, Fang Z, Wu Z, Jiang H, Xu J, Gao P. Mesenchymal stem cells in prostate cancer have higher expressions of SDF-1, CXCR4 and VEGF. Gen Physiol Biophys. 2013;32(2):245-250.

Gu X, Na R, Huang T, Wang L, Tao S, Tian L, Chen Z, Jiao Y, Kang J, Zheng S, Xu J, Sun J, Qi J. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5 alpha-reductase inhibitors and alpha-adrenergic receptor antagonists. J Urol. 2013;190(2):615-619.

Simonds NI, Khoury MJ, Schully SD, Armstrong K, Cohn WF, Fenstermacher DA, Ginsburg GS, Goddard KA, Knaus WA, Lyman GH, Ramsey SD, Xu J, Freedman AN. Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects [commentary]. J Natl Cancer Inst. 2013;105(13):929-936.

Han Y, Sun W, Wang L, Tao S, Tian L, Hao Y, Zhang W, Wu S, Li S, Lv H, Zheng SL, Sun J, Xu J. HDAC9 gene is associated with stroke risk in a Chinese population. Exp Biol Med (Maywood). 2013;238(7):842-847.

Shao Q, Xu J, Adams T, Tao S, Cui Y, Shen H, Cao W, Xie J, Fan Y, Zhang Y, Huang M. Comparison of aspiration-sclerotherapy versus laparoscopic decortication in management of symptomatic simple renal cysts. J Xray Sci Technol. 2013;21(3):419-428.


Jiang H, Liu F, Wang Z, Na R, Zhang L, Wu Y, Zheng J, Lin X, Jiang D, Sun J, Zheng SL, Ding Q, Xu J. Prediction of prostate cancer from prostate biopsy in Chinese men using a genetic score derived from 24 prostate cancer risk-associated SNPs. Prostate. 2013;73(15):1651-1659.

Na R, Liu F, Zhang P, Ye D, Xu C, Shao Q, Qi J, Wang X, Chen Z, Wang M, He D, Wang Z, Zhou F, Yuan J, Gao X, Wei Q, Yang J, Jiao Y, Ou-Yang J, Zhu Y, Wu Q, Chen H, Lu D, Shi R, Lin X, Jiang H, Wang Z, Jiang D, Sun J,. Evaluation of reported prostate cancer risk-associated SNPs from genome-wide association studies of various racial populations in Chinese men. Prostate. 2013;73(15):1623-1635.

Stovall DB, Wan M, Miller LD, Cao P, Maglic D, Zhang Q, Stampfer MR, Liu W, Xu J, Sui G. The regulation of SOX7 and its tumor suppressive role in breast cancer. Am J Pathol. 2013;183(5):1645-1653.

Chen Z, Tao S, Gao Y, Zhang J, Hu Y, Mo L, Kim ST, Yang X, Tan A, Zhang H, Qin X, Li L, Wu Y, Zhang S, Zheng SL, Xu J, Mo Z, Sun J. Genome-wide association study of sex hormones, gonadotropins and sex hormone-binding protein in Chinese men. J Med Genet. 2013;50(12):794-801.

Chen Y, Xin X, Li J, Xu J, Yu X, Li T, Mo Z, Hu Y. RTK/ERK pathway under natural selection associated with prostate cancer. PLoS One. 2013;8(11):e78254.

Zhou L, He M, Mo Z, Wu C, Yang H, Yu D, Yang X, Zhang X, Wang Y, Sun J, Gao Y, Tan A, He Y, Zhang H, Qin X, Zhu J, Li H, Lin X, Zhu J, Min X, Lang M, Li D, Zhai K, Chang J, Tan W, Yuan J, Chen W, Wang Y, Wei S, Miao X, Wang F, Fang W, Liang Y, Deng Q,. A genome wide association study identifies common variants associated with lipid levels in the Chinese population. PLoS One. 2013;8(12):e82420.

Szulkin R, Holmberg E, Stattin P, Xu J, Zheng S, Palmgren J, Gronberg H, Wiklund F. Prostate cancer risk variants are not associated with disease progression. Prostate. 2012;72(1):30-39.

Feng J, Kim S-T, Liu W, Kim JW, Zhang Z, Zhu Y, Berens M, Sun J, Xu J. An integrated analysis of germline and somatic, genetic and epigenetic alterations at 9p21.3 in glioblastoma. Cancer. 2012;118(1):232-240.

Lu Y, Sun J, Kader AK, Kim S-T, Kim J-W, Liu W, Sun J, Lu D, Feng J, Zhu Y, Jin T, Zhang Z, Dimitrov L, Lowey J, Campbell K, Suh E, Duggan D, Carpten J, Trent JM, Gronberg H, Zheng SL, Isaacs WB, Xu J. Association of prostate cancer risk with SNPs in regions containing androgen receptor binding sites captured by ChIP-On-chip analyses. Prostate. 2012;72(4):376-385.

Lu L, Cancel-Tassin G, Valeri A, Cussenot O, Lange EM, Cooney KA, Farnham JM, Camp NJ, Zheng SL, Xu J, et al. Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG. Prostate. 2012;72(4):410-426.

Shao Q, Ouyang J, Fan Y, Xie J, Zhou J, Wu J, Kader AK, Xu J, Liu G, Shan Y, Wen D, Zhang Y. Prostate cancer in the senior men from rural areas in east district of China: contemporary management and 5-year outcomes at multi-institutional collaboration. Cancer Lett. 2012;315(2):170-177.

Wang M, Liu F, Hsing AW, Wang X, Shao Q, Zhang Y, Jin G, Sun J, Zheng SL, Xu J, et al. Replication and cumulative effects of GWAS-identified genetic variations for prostate cancer in Asians: a case-control study in the ChinaPCa consortium. Carcinogenesis. 2012;33(2):356-360.

Hester JM, Wing MR, Li J, Palmer ND, Xu J, Hicks PJ, Roh BH, Norris JM, Wagenknecht LE, Langefeld CD, Freedman BI, Bowden DW, Ng MCY. Implication of European-derived adiposity loci in African Americans. Int J Obes (Lond). 2012;36(3):465-473.

Palmer N, Turner A, Xu J, Avis N. African-American prostate cancer survivors' treatment decision-making and quality of life [abstract]. Psychooncology. 2012;21(Suppl 1):18-19.

Tao S, Wang Z, Feng J, Hsu F-C, Jin G, Kim S-T, Zhang Z, Gronberg H, Zheng LS [sic] [Zheng SL], Isaacs WB, Xu J, Sun J. A genome-wide search for loci interacting with known prostate cancer risk-associated genetic variants. Carcinogenesis. 2012;33(3):598-603.

Wen W, Cho Y-S, Zheng W, Dorajoo R, Kato N, Qi L, Chen C-H, Delahanty RJ, Okada Y, Xu J, et al. Meta-analysis identifies common variants associated with body mass index in east Asians. Nat Genet. 2012;44(3):307-311.

Zheng J, Liu F, Lin X, Wang X, Ding Q, Jiang H, Chen H, Lu D, Jin G, Hsing AW, Shao Q, Qi J, Ye Y, Wang Z, Gao X, Wang G, Chu LW, OuYang J, Huang Y, Chen Y, Gao Y, Shi R, Wu Q, Wang M, Zhang Z, Hu Y, Sun J, Zheng SL, Gao X, Xu C. Predictive performance of prostate cancer risk in Chinese men using 33 reported prostate cancer risk-associated SNPs. Prostate. 2012;72(5):577-583.


Newcombe PJ, Reck BH, Sun JL, Platek GT, Verzilli C, Kader AK, Kim ST, Jin T, Zhang Z, Zheng SL, Mooser VE, Condreay LD, Spraggs CF, Whittaker JC, Rittmaster RS, Xu JF. Comparison of methods for evaluating the predictive benefit of genetic information for prostate cancer risk [abstract]. Genet Epidemiol. 2012;36(2):155-156.

Wu M, Shi L, Cimic A, Romero L, Sui G, Lees CJ, Cline JM, Seals DF, Sirintrapun JS, McCoy TP, Liu W, Kim JW, Hawkins GA, Peehl DM, Xu J, Cramer SD. Suppression of Tak1 promotes prostate tumorigenesis. Cancer Res. 2012;72(11):2833-2843.

Sekulic A, Zismann V, Froman R, Allen A, Huentleman M, Paoloni M, Neff M, Davis B, Cox A, Duesbery N, Xu J, Bittner M, Webb C, Brown K, LoRusso P, Trent J. Efforts to provide a comprehensive overview of genetic changes in canine melanoma as a means to identify genetic correlates for drug response [abstract]. J Invest Dermatol. 2012;132(Suppl 1):S133.

Tan A, Sun J, Xia N, Qin X, Hu Y, Zhang S, Tao S, Gao Y, Yang X, Zhang H, Kim S-T, Peng T, Lin X, Li L, Mo L, Liang Z, Shi D, Huang Z, Huang X, Liu M, Ding Q, Trent JM, Zheng SL, Mo Z, Xu J. A genome-wide association and gene-environment interaction study for serum triglycerides levels in a healthy Chinese male population. Hum Mol Genet. 2012;21(7):1658-1664.

Newcombe PJ, Reck BH, Sun J, Platek GT, Verzilli C, Kader AK, Kim S-T, Hsu F-C, Zhang Z, Zheng SL, Mooser VE, Condreay LD, Spraggs CF, Whittaker JC, Rittmaster RS, Xu J. A comparison of Bayesian and Frequentist approaches to incorporating external information for the prediction of prostate cancer risk. Genet Epidemiol. 2012;36(1):71-83.

Lin X, Lu D, Gao Y, Tao S, Yang X, Feng J, Tan A, Zhang H, Hu Y, Qin X, Kim ST, Peng T, Li L, Mo L, Zhang S, Trent JM, Mo Z, Zheng SL, Xu J, Sun J. Genome-wide association study identifies novel loci associated with serum level of vitamin B12 in Chinese men. Hum Mol Genet. 2012;21(11):2610-2617.

Zhao H, Xu J, Zhang H, Sun J, Sun Y, Wang Z, Liu J, Ding Q, Lu S, Shi R, You L, Qin Y, Zhao X, Lin X, Li X, Feng J, Wang L, Trent JM, Xu C, Gao Y, Zhang B, Gao X, Hu J, Chen H, Li G, Zhao J, Zou S, Jiang H, Hao C, Zhao Y, Ma J, Zheng SL, Chen ZJ. A genome-wide association study reveals that variants within the HLA region are associated with risk for nonobstructive azoospermia. Am J Hum Genet. 2012;90(5):900-906.

Herrington DM, Meyers DA, Xu J, Zheng SL, Bleecker ER, Isaacs WB, Walsh PC, inventors; Wake Forest University Health Sciences, assignee. Mutations in the macrophage scavenger receptor 1 gene alter risk of prostate cancer, asthma, and cardiovascular disease. United States patent US 8,192,928. 2012 June 5. 2012;():.

Tao S, Feng J, Webster T, Jin G, Hsu F-C, Chen S-H, Kim S-T, Wang Z, Zhang Z, Zheng SL, Isaacs WB, Xu J, Sun J. Genome-wide two-locus epistasis scans in prostate cancer using two European populations. Hum Genet. 2012;131(7):1225-1234.

Chen SH, Ip EH, Xu J, Sun J, Hsu FC. Using graded response model for the prediction of prostate cancer risk. Hum Genet. 2012;131(8):1327-1336.

Jin G, Lu L, Cooney KA, Ray AM, Zuhlke KA, Lange EM, Cannon-Albright LA, Camp NJ, Teerlink CC, Fitzgerald LM, Stanford JL, Wiley KE, Isaacs SD, Walsh PC, Foulkes WD, Giles GG, Hopper JL, Severi G, Eeles R, Easton D, Kote-Jarai Z, Guy M,. Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet. 2012;131(7):1095-1103.

Thomas JA II, Gerber L, Moreira DM, Hamilton RJ, Banez LL, Castro-Santamaria R, Andriole GL, Isaacs WB, Xu J, Freedland SJ. Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1). J Intern Med. 2012;272(1):85-92.

Liu W, Lindberg J, Sui G, Luo J, Egevad L, Li T, Xie C, Wan M, Kim S-T, Wang Z, Turner AR, Zhang Z, Feng J, Yan Y, Sun J, Bova GS, Ewing CM, Yan G, Gielzak M, Cramer SD, Vessella RL, Zheng SL, Gronberg H, Isaacs WB, Xu J. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene. 2012;31(35):3939-3948.

Ding GX, Liu J, Feng CC, Jiang HW, Xu JF, Ding Q. Slug regulates cyclin D1 expression by ubiquitin-proteasome pathway in prostate cancer cells. Panminerva Med. 2012;54(3):219-223.


Kim JW, Kim ST, Turner AR, Young T, Smith S, Liu W, Lindberg J, Egevad L, Gronberg H, Isaacs WB, Xu J. Identification of new differentially methylated genes that have potential functional consequences in prostate cancer. PLoS One. 2012;7(10):e48455.

Kader AK, Sun J, Reck BH, Newcombe PJ, Kim ST, Hsu FC, D'Agostino RB Jr, Tao S, Zhang Z, Turner AR, Platek GT, Spraggs CF, Whittaker JC, Lane BR, Isaacs WB, Meyers DA, Bleecker ER, Torti FM, Trent JM, McConnell JD,. Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol. 2012;62(6):953-961.


He J, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, Rybicki BA, Isaacs W, Ingles SA, Stanford JL, Diver RW, Witte JS, Hsing A, Nemesure B, Rebbeck TR, Cooney KA, Xu J, Kibel AS, Hu JJ, John EM, Gueye SM, Watya S, Signorello LB,. Polygenes and estimated heritability of prostate cancer in an African American sample using GWAS data [abstract]. Genet Epidemiol. 2012;36(7):736.


Liu J, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, Rybicki BA, Isaacs W, Ingles SA, Stanford JL, Diver WR, Witte JS, Hsing AW, Nemesure B, Rebbeck TR, Cooney KA, Xu J, Kibel AS, Hu JJ, John EM, Gueye SM, Watya S, Signorello LB,. Models for admixture mapping in a regression framework [abstract]. Genet Epidemiol. 2012;36(7):727.

Na R, Jiang H, Kim ST, Wu Y, Tong S, Zhang L, Xu J, Sun Y, Ding Q. Outcomes and trends of prostate biopsy for prostate cancer in Chinese men from 2003 to 2011. PLoS One. 2012;7(11):e49914.

Xu J, Mo Z, Ye D, Wang M, Liu F, Jin G, Xu C, Wang X, Shao Q, Chen Z, Tao Z, Qi J, Zhou F, Wang Z, Fu Y, He D, Wei Q, Guo J, Wu D, Gao X, Yuan J, Wang G, Xu Y, Wang G, Yao H, Dong P, Jiao Y, Shen M, Yang J,. Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat Genet. 2012;44(11):1231-1235.

Yang X, Sun J, Gao Y, Tan A, Zhang H, Hu Y, Feng J, Qin X, Tao S, Chen Z, Kim ST, Peng T, Liao M, Lin X, Zhang Z, Tang M, Li L, Mo L, Liang Z, Shi D, Huang Z, Huang X, Liu M, Liu Q, Zhang S, Trent JM, Zheng SL, Xu J, Mo Z. Genome-wide association study for serum complement C3 and C4 levels in healthy Chinese subjects. PLoS Genet. 2012;8(9):e1002916.

Zuhlke KA, Johnson AM, Okoth LA, Stoffel EM, Robbins CM, Tembe WA, Salinas CA, Zheng SL, Xu J, Carpten JD, Lange EM, Isaacs WB, Cooney KA. Identification of a novel NBN truncating mutation in a family with hereditary prostate cancer. Fam Cancer. 2012;11(4):595-600.

Bailey-Wilson JE, Childs EJ, Cropp CD, Schaid DJ, Xu J, Camp NJ, Cannon-Albright LA, Farnham JM, George A, Powell I, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, Foulkes WD, Maehle L, Moller P, Eeles R, Easton D,. Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families. BMC Med Genet. 2012;13():46.

Jin G, Sun J, Kim ST, Feng J, Wang Z, Tao S, Chen Z, Purcell L, Smith S, Isaacs WB, Rittmaster RS, Zheng SL, Condreay LD, Xu J. Genome-wide association study identifies a new locus JMJD1C at 10q21 that may influence serum androgen levels in men. Hum Mol Genet. 2012;21(23):5222-5228.

Liu W, Feng J, Xu J. A picture with more details is painted for prostate cancer. Asian J Androl. 2012;14(6):799-800.

Yang M, Wu Y, Lu Y, Liu C, Sun J, Liao M, Qin M, Mo L, Gao Y, Lu Z, Wu C, Zhang Y, Zhang H, Qin X, Hu Y, Zhang S, Li J, Dong M, Zheng SL, Xu J, Yang X, Tan A, Mo Z. Genome-wide scan identifies variant in TNFSF13 associated with serum IgM in a healthy Chinese male population. PLoS One. 2012;7(10):e47990.

Sun J, Kader AK, Hsu F-C, Kim S-T, Zhu Y, Turner AR, Jin T, Zhang Z, Zheng SL, Xu J, et al. Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer. Prostate. 2011;71(4):421-430.

Chang B-L, Spangler E, Gallagher S, Haiman CA, Henderson B, Isaacs W, Benford ML, Kidd LR, Cooney K, Xu J, et al. Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev. 2011;20(1):23-32.

Reed SD, Scales CD Jr, Stewart SB, Sun J, Moul JW, Schulman KA, Xu J. Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer. J Urol. 2011;185(3):841-847.

Chen H, Chen Y, Zhao Y, Fan W, Zhou K, Liu Y, Zhou L, Mao Y, Wei Q, Xu J, Lu D. Association of sequence variants on chromosomes 20, 11, and 5 (20q13.33, 11q23.3, and 5p15.33) with glioma susceptibility in a Chinese population. Am J Epidemiol. 2011;173(8):915-922.

Yu G, Zhang B, Bova GS, Xu J, Shih I-M, Wang Y. BACOM: in silico detection of genomic deletion types and correction of normal cell contamination in copy number data. Bioinformatics. 2011;27(11):1473-1480.

Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, Rybicki BA, Isaacs WB, Xu J, Zheng SL, et al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet. 2011;43(6):570-573.

Lu Y, Zhang Z, Yu H, Zheng SL, Isaacs WB, Xu J, Sun J. Functional annotation of risk loci identified through genome-wide association studies for prostate cancer. Prostate. 2011;71(9):955-963.

Aly M, Wiklund F, Xu J, Isaacs WB, Eklund M, D'Amato M, Adolfsson J, Gronberg H. Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study. Eur Urol. 2011;60(1):21-28.

Chung CC, Ciampa J, Yeager M, Jacobs KB, Berndt SI, Hayes RB, Gonzalez-Bosquet J, Kraft P, Wacholder S, Xu J, et al. Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer. Hum Mol Genet. 2011;20(14):2869-2878.

Jin G, Sun J, Liu W, Zhang Z, Chu LW, Kim S-T, Sun J, Feng J, Zheng SL, Xu J, et al. Genome-wide copy-number variation analysis identifies common genetic variants at 20p13 associated with aggressiveness of prostate cancer. Carcinogenesis. 2011;32(7):1057-1062.

Berndt SI, Sampson J, Yeager M, Jacobs KB, Wang Z, Hutchinson A, Chung C, Xu J, Zheng SL, Sun J, et al. Large-scale fine mapping of the HNF1B locus and prostate cancer risk. Hum Mol Genet. 2011;20(16):3322-3329.

Xie CC, Lu L, Sun J, Zheng SL, Isaacs WB, Gronberg H, Xu J. Germ-line sequence variants of PTEN do not have an important role in hereditary and non-hereditary prostate cancer susceptibility. J Hum Genet. 2011;56(7):496-502.

Wang M, Chu H, Yan F, Qin C, Li P, Yuan L, Yin C, Xu J, Zhang Z. Chromosome 4p16.3 variant modify bladder cancer risk in a Chinese population. Carcinogenesis. 2011;32(6):872-875.

Humphreys K, Grankvist A, Leu M, Hall P, Liu J, Ripatti S, Rehnstrom K, Groop L, Klareskog L, Xu J, et al. The genetic structure of the Swedish population. PLoS ONE. 2011;6(8):e22547.

Lin DW, FitzGerald LM, Fu R, Kwon EM, Zheng SL, Kolb S, Wiklund F, Stattin P, Isaacs WB, Xu J, et al. Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev. 2011;20(9):1928-1936.

Cheng Y, Liu W, Kim S-T, Sun J, Lu L, Sun J, Zheng SL, Isaacs WB, Xu J. Evaluation of PPP2R2A as a prostate cancer susceptibility gene: a comprehensive germline and somatic study. Cancer Genet. 2011;204(7):375-381.

Schumacher FR, Berndt SI, Siddiq A, Jacobs KB, Wang Z, Lindstrom S, Stevens VL, Chen C, Mondul AM, Xu J, et al. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet. 2011;20(19):3867-3875.

Cox AJ, Wing MR, Carr JJ, Hightower RC, Smith SC, Xu J, Wagenknecht LE, Bowden DW, Freedman BI. Association of PNPLA3 SNP rs738409 with liver density in African Americans with type 2 diabetes mellitus. Diabetes Metab. 2011;37(5):452-455.

Cooke J, Ng M, Lu L, Li J, An S, Hester J, Xu J, Freedman B, Langefeld C, Bowden D, Palmer N. Genetic risk assessment of type 2 diabetes associated polymorphisms in African-Americans [abstract]. In: Abstracts of the 61st Annual Meeting of the American Society of Human Genetics; 2011 Oct 11-15; Montreal (Canada). 2011;():.

Liu F, Hsing AW, Wang X, Shao Q, Qi J, Ye Y, Jin G, Sun J, Zheng SL, Xu J, et al. Systematic confirmation study of reported prostate cancer risk-associated single nucleotide polymorphisms in Chinese men. Cancer Sci. 2011;102(10):1916-1920.

Feng J, Sun J, Kim S-T, Lu Y, Wang Z, Zhang Z, Gronberg H, Isaacs WB, Zheng SL, Xu J. A genome-wide survey over the ChIP-on-chip identified androgen receptor-binding genomic regions identifies a novel prostate cancer susceptibility locus at 12q13.13. Cancer Epidemiol Biomarkers Prev. 2011;20(11):2396-2403.

Jin G, Sun J, Isaacs SD, Wiley KE, Kim S-T, Chu LW, Zhang Z, Zhao H, Zheng SL, Isaacs WB, Xu J. Human polymorphisms at long non-coding RNAs (lncRNAs) and association with prostate cancer risk. Carcinogenesis. 2011;32(11):1655-1659.

Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, Han M, Netto GJ, Isaacs WB, De Marzo AM. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res. 2011;17(20):6563-6573.

Xu J, Chang B-L, Cramer SD, Rao A, inventors; Wake Forest University Health Sciences, assignee. Genetic polymorphisms in the prostate-specific antigen gene promoter. United States patent US 7,993,843. 2011 Aug 9. 2011;():.

Lindstrom S, Hunter DJ, Gronberg H, Stattin P, Wiklund F, Xu J, Chanock SJ, Hayes R, Kraft P. Sequence variants in the TLR4 and TLR6-1-10 genes and prostate cancer risk. Results based on pooled analysis from three independent studies. Cancer Epidemiol Biomarkers Prev. 2010;19(3):873-876.


Xu J, Zheng SL, Isaacs SD, Wiley KE, Sun J, Kader AK, Li G, Purcell LD, Kim S-T, Hsu F-C, et al. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc Natl Acad Sci U S A. 2010;107(5):2136-2140.

Zheng SL, Hsing AW, Sun J, Chu LW, Yu K, Li G, Gao Z, Kim S-T, Isaacs WB, Xu J, et al. Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men. Prostate. 2010;70(4):425-432.

Hsu F-C, Sun J, Zhu Y, Kim S-T, Jin T, Zhang Z, Wiklund F, Kader AK, Zheng SL, Xu J, et al. Comparison of two methods for estimating absolute risk of prostate cancer based on single nucleotide polymorphisms and family history. Cancer Epidemiol Biomarkers Prev. 2010;19(4):1083-1088.

Klein RJ, Hallden C, Cronin AM, Ploner A, Wiklund F, Bjartell AS, Stattin P, Xu J, Scardino PT, Offit K, et al. Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer. Cancer Prev Res (Phila Pa). 2010;3(5):611-619.

Prokunina-Olsson L, Fu Y-P, Tang W, Jacobs KB, Hayes RB, Kraft P, Berndt SI, Wacholder S, Yu K, Xu J, et al. Refining the prostate cancer genetic association within the JAZF1 gene on chromosome 7p15.2. Cancer Epidemiol Biomarkers Prev. 2010;19(5):1349-1355.

Ohar JA, Hamilton RF Jr, Zheng S, Sadeghnejad A, Sterling DA, Xu J, Meyers DA, Bleecker ER, Holian A. COPD is associated with a macrophage scavenger receptor-1 gene sequence variation. Chest. 2010;137(5):1098-1107.

Christensen GB, Baffoe-Bonnie AB, George A, Powell I, Bailey-Wilson JE, Carpten JD, Giles GG, Hopper JL, Dimitrov L, Xu J, et al. Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses. Prostate. 2010;70(7):735-744.

Cao P, Deng Z, Wan M, Huang W, Cramer SD, Xu J, Lei M, Sui G. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer. 2010;9():108.

Cramer SD, Rao A, Xu J, Chang B-l, inventors; Wake Forest University Health Sciences, assignee. Genetic polymorphisms in the prostate-specific antigen gene promoter. United States patent US 7,718,372. 2010 May 18. 2010;():.

Elliott KS, Zeggini E, McCarthy MI, Gudmundsson J, Sulem P, Stacey SN, Thorlacius S, Amundadottir L, Gronberg H, Xu J, et al. Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies. PLoS ONE. 2010;5(5):e10858.

Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet. 2010;42(8):668-675.

Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Rivadeneira F, Willer CJ, Jackson AU, Vedantam S, Xu J, et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height [research letter]. Nature. 2010;467(7317):832-838.

Feng J, Sun J, Wang MZ, Zhang Z, Kim ST, Zhu Y, Sun J, Xu J. Compilation of a comprehensive gene panel for systematic assessment of genes that govern an individual's drug responses. Pharmacogenomics. 2010;11(10):1403-1425.

Kim S-T, Cheng Y, Hsu F-C, Jin T, Kader AK, Zheng SL, Isaacs WB, Xu J, Sun J. Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic variation. Prostate. 2010;70(16):1729-1738.

Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, Allen HL, Lindgren CM, Luan J, Xu J, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010;42(11):937-948.

Gronberg H, Xu J, Isaacs WB. Individualized prediction of prostate cancer using genetic markers [abstract]. EJC Suppl. 2010;8(5):158.

Kim JW, Cheng Y, Liu W, Li T, Yegnasubramanian S, Zheng SL, Xu J, Isaacs WB, Chang B-L. Genetic and epigenetic inactivation of LPL gene in human prostate cancer. Int J Cancer. 2009;124(3):734-738.

Cheng Y, Kim JW, Liu W, Dunn TA, Luo J, Loza MJ, Kim S-T, Zheng SL, Xu J, Chang B-L, et al. Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer. Prostate. 2009;69(3):327-335.

Sun J, Zheng SL, Li G, Kim S-T, Zhu Y, Zhang Z, Hsu F-C, Turner AR, Liu W, Kim JW, Xu J, Chang B-L, et al. Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res. 2009;69(1):10-15.

Bleyer AJ, Hire D, Russell GB, Xu J, Divers J, Shihabi Z, Bowden DW, Freedman BI. Ethnic variation in the correlation between random serum glucose concentration and glycated haemoglobin. Diabet Med. 2009;26(2):128-133.

Zheng SL, Sun J, Gao Z, Purcell LD, Hsu F-C, Zhu Y, Turner AR, Adams TS, Liu W, Chang B-L, Xu J, et al. Genetic variants and family history predict prostate cancer similar to prostate-specific antigen. Clin Cancer Res. 2009;15(3):1105-1111.

Liu W, Sun J, Li G, Zhu Y, Zhang S, Kim S-T, Sun J, Xu J, Zheng SL, Chang B-L, et al. Association of a germ-line copy number variation at 2p24.3 and risk for aggressive prostate cancer. Cancer Res. 2009;69(6):2176-2179.

Wiklund F, Zheng SL, Sun J, Adami H-O, Lilja H, Hsu F-C, Stattin P, Cramer SD, Chang B-L, Xu J, et al. Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. Prostate. 2009;69(4):419-427.

Chang B-L, Cramer SD, Sun J, Smith S, Pruett K, Romero LM, Zhu Y, Zhang Z, Hsu F-C, Turner AR, Liu W, Kim JW, Zheng SL, Xu J, et al. Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Hum Mol Genet. 2009;18(7):1368-1375.

Hsu F-C, Sun J, Purcell LD, Gao Z, Zhu Y, Kim S-T, Zhang Z, Liu W, Chang B-L, Xu J, Zheng SL, et al. A novel prostate cancer susceptibility locus at 19q13. Cancer Res. 2009;69(7):2720-2723.

Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing CM, Eisenberger MA, Xu J, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer [research letter]. Nat Med. 2009;15(5):559-565.

Zheng SL, Sun J, Smith S, Pruett K, Kim S-T, Zhu Y, Zhang Z, Hsu F-C, Turner AR, Liu W, Kim JW, Chang B-L, Xu J, et al. Two independent prostate cancer risk-associated Loci at 11q13. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1815-1820.

Xu J, Sun J, Kader AK, Lindstrom S, Wiklund F, Hsu F-C, Kim S-T, Johansson J-E, Zheng SL, Platz EA, et al. Estimation of absolute risk for prostate cancer from blood DNA [abstract]. J Urol. 2009;181(4 Suppl):643.

Wiklund FE, Adami H-O, Zheng SL, Stattin P, Isaacs WB, Gronberg H, Xu J. Established prostate cancer susceptibility variants are not associated with disease outcome. Cancer Epidemiol Biomarkers Prev. 2009;18(5):1659-1662.

Kader AK, Sun J, Isaacs SD, Wiley KE, Yan G, Kim S-T, Fedor H, DeMarzo AM, Zheng SL, Xu J, et al. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate. 2009;69(11):1195-1205.

Lu L, Sun J, Isaacs SD, Smith S, Pruett K, Zhu Y, Zhang Z, Chang B-L, Zheng SL, Xu J, et al. Fine-mapping and family-based association analyses of prostate cancer risk variants at Xp11. Cancer Epidemiol Biomarkers Prev. 2009;18(7):2132-2136.

Xu J, Kibel AS, Turner AR, Pruett K, Zheng SL, Sun J, Kim S-T, Hsu F-C, Torti FM, Chang B-L, et al. Prostate cancer risk associated loci in African Americans. Cancer Epidemiol Biomarkers Prev. 2009;18(7):2145-2149.

Zhang W, Sun K, Zhen Y, Wang D, Wang Y, Chen J, Xu J, Hu FB, Hui R. VEGF receptor-2 variants are associated with susceptibility to stroke and recurrence. Stroke. 2009;40(8):2720-2726.

Khoury MJ, McBride CM, Schully SD, Ioannidis JPA, Feero WG, Janssens ACJW, Gwinn M, Simons-Morton DG, Bernhardt JM, Xu J, et al. The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med. 2009;11(8):559-567.

Xu J, Sun J, Kader AK, Lindstrom S, Wiklund F, Hsu F-C, Johansson J-E, Zheng SL, Thomas G, Hayes RB, et al. Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate. 2009;69(14):1565-1572.

Lindstrom S, Adami H-O, Balter K, Xu J, Zheng SL, Sun J, Stattin P, Gronberg H, Wiklund F. Genetic variation in the upstream region of ERG and prostate cancer. Cancer Causes Control. 2009;20(7):1173-1180.

Yeager M, Chatterjee N, Ciampa J, Jacobs KB, Gonzalez-Bosquet J, Hayes RB, Kraft P, Xu J, Zheng SL, Sun J, et al. Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet. 2009;41(10):1055-1057.

Brown DA, Lindmark F, Stattin P, Balter K, Adami H-O, Zheng SL, Xu J, Isaacs WB, Gronberg H, Breit SN, et al. Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. Clin Cancer Res. 2009;15(21):6658-6664.

Koppelman GH, Meyers DA, Howard TD, Zheng SL, Hawkins GA, Ampleford EJ, Xu J, Koning H, Bruinenberg M, Bleecker ER, et al. Identification of PCDH1 as a novel susceptibility gene for bronchial hyperresponsiveness. Am J Respir Crit Care Med. 2009;180(10):929-935.

Bostrom MA, Lu L, Chou J, Hicks PJ, Xu J, Langefeld CD, Freedman BI, Bowden DW. Genome wide association study of non-diabetic end stage renal disease in African Americans using pooled DNA [abstract]. Presented at the 59th Annual Meeting of The American Society of Human Genetics, October 21, 2009, Honolulu, Hawaii. 2009;():A676.

Koppelman GH, Meyers DA, Howard TD, Zheng SL, Hawkins GA, Ampleford EA, Xu J, Koning H, Bruinenberg M, Bleecker ER, et al. Identification of protocadherin-1 as a novel susceptibility gene for bronchial hyperresponsiveness and asthma [abstract]. Am J Respir Crit Care Med. 2009;179(1 Meeting Abstracts):A2447.

Xu J, Zheng SL, Herrington DM, Bleecker E, Meyers D, Isaacs W, Walsh P, inventors; Wake Forest University Health Sciences, assignee. Mutations in the macrophage scavenger receptor 1 gene alter risk of prostate cancer, asthma, and cardiovascular disease. United States patent US 7,579,147. 2009 Aug 25. 2009;():.

Freedman BI, Bowden DW, Rich SS, Xu J, Wagenknecht LE, Ziegler J, Hicks PJ, Langefeld CD. Genome-wide linkage scans for renal function and albuminuria in type 2 diabetes mellitus: the Diabetes Heart Study. Diabet Med. 2008;25(3):268-276.

Sun J, Lange EM, Isaacs SD, Liu W, Wiley KE, Lange L, Gronberg H, Xu J, Chang B-L, Zheng SL, et al. Chromosome 8q24 risk variants in hereditary and non-hereditary prostate cancer patients. Prostate. 2008;68(5):489-497.

Zheng SL, Sun J, Smith S, Li G, Hsu F-C, Zhu Y, Kader AK, Turner AR, Liu W, Bleecker ER, Meyers DA, Chang B-L, Xu J, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008;358(9):910-919.

Chen S-H, Sun J, Dimitrov L, Turner AR, Adams TS, Meyers DA, Chang B-L, Zheng SL, Xu J, Hsu F-C, et al. A support vector machine approach for detecting gene-gene interaction. Genet Epidemiol. 2008;32(2):152-167.

Gudmundsson J, Sulem P, Rafnar T, Bergthorsson JT, Manolescu A, Gudbjartsson D, Zheng SL, Sun J, Chang B-L, Xu J, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet. 2008;40(3):281-283.

Sun J, Purcell L, Gao Z, Isaacs SD, Wiley KE, Hsu F-C, Liu W, Xu J, Chang B-L, Zheng SL, et al. Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. Prostate. 2008;68(7):691-697.

Jacobs EJ, Hsing AW, Bain EB, Stevens VL, Wang Y, Chen J, Chanock SJ, Zheng SL, Xu J, Thun MJ, et al. Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(4):972-977.

Hsu F-C, Lindstrom S, Sun J, Wiklund F, Turner AR, Liu W, Kim JW, Chang B-l, Xu J, Zheng SL, et al. A multigenic approach to evaluating prostate cancer risk in a systematic replication study. Cancer Genet Cytogenet. 2008;183(2):94-98.

Kader AK, Sun J, Yang G, Zheng L, Xu J, Liu W, Issacs WB. Loss of chromosome 17p13.1 significantly correlates with Gleason score at the time of radical prostatectomy [abstract]. J Urol. 2008;179(4 Suppl):227-228.

Xu JF, Isaacs WB, Gronberg H. Five genetic variants associated with prostate cancer [reply to letter]. N Engl J Med. 2008;358(25):2741.

Sun J, Chang B-L, Isaacs SD, Wiley KE, Wiklund F, Stattin P, Duggan D, Carpten JD, Xu J, Zheng SL, et al. Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. Prostate. 2008;68(12):1257-1262.

Bowden DW, Lehtinen AB, Ziegler JT, Rudock ME, Xu J, Wagenknecht LE, Herrington DM, Rich SS, Freedman BI, Carr JJ, Langefeld CD. Genetic epidemiology of subclinical cardiovascular disease in the Diabetes Heart Study. Ann Hum Genet. 2008;72(Pt 5):598-610.

Cramer SD, Sun J, Zheng SL, Xu J, Peehl DM. Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(9):2451-2457.

Sun J, Zheng SL, Purcell LD, Gao Z, Hsu F-C, Kim S-T, Liu W, Zhu Y, Dimitrov L, Sun J, Li T, Turner AR, Adams TS, Chang B-L, Xu J, et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet. 2008;40(10):1153-1155.

Xu J, Sun J, Li G, Zhu Y, Hsu F-C, Turner AR, Adams TS, Liu W, Chang B, Zheng S, et al. Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res. 2008;14(18):5819-5824.

Lange EM, Sun J, Lange LA, Zheng SL, Duggan D, Carpten JD, Gronberg H, Isaacs WB, Xu J, Chang B-L. Family-based samples can play an important role in genetic association studies [commentary]. Cancer Epidemiol Biomarkers Prev. 2008;17(9):2208-2214.

Liu W, Xie CC, Zhu Y, Li T, Sun J, Cheng Y, Turner AR, Sun J, Chang B-L, Zheng SL, Xu J, et al. Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia. 2008;10(8):897-907.

Stevens VL, Hsing AW, Talbot JT, Zheng SL, Sun J, Chen J, Thun MJ, Xu J, Calle EE, Rodriguez C. Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk. Int J Cancer. 2008;123(11):2644-2650.

Ohar JA, Holian A, Sadeghnejad A, Hamilton RF, Zheng SL, Xu J, Meyers DA, Bleecker ER. Polymorphisms in MSR1 gene affect macrophage function [abstract]. Am J Respir Crit Care Med. 2008;177(Online Abstr Issue):A503.

Liu W, Chang B, Li T, Dimitrov L, Kim S, Kim JW, Turner AR, Meyers DA, Zheng SL, Xu J, et al. Germline copy number polymorphisms involving larger than 100 kb are uncommon in normal subjects. Prostate. 2007;67(3):227-233.

Lakoski SG, Li L, Langefeld CD, Liu Y, Howard TD, Brosnihan KB, Xu J, Bowden DW, Herrington DM. The association between innate immunity gene (IRAK1) and C-reactive protein in the Diabetes Heart Study. Exp Mol Pathol. 2007;82(3):280-283.

Sun J, Liu W, Adams TS, Sun J, Li X, Turner AR, Chang B, Kim JW, Zheng SL, Xu J, et al. DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate. 2007;67(7):692-700.

De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7(4):256-269.


Sun J, Turner A, Xu J, Gronberg H, Isaacs W. Genetic variability in inflammation pathways and prostate cancer risk. Urol Oncol. 2007;25(3):250-259.

Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, Rafnar T, Bergthorsson JT, Agnarsson BA, Xu J, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet. 2007;39(5):631-637.

Camp NJ, Cannon-Albright LA, Farnham JM, Baffoe-Bonnie AB, George A, Powell I, Bailey-Wilson JE, Carpten JD, Dimitrov L, Xu J, et al. Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Hum Mol Genet. 2007;16(11):1271-1278.

Kouprina N, Noskov VN, Solomon G, Otstot J, Isaacs W, Xu J, Schleutker J, Larionov V. Mutational analysis of SPANXgenes in families with X-linked prostate cancer. Prostate. 2007;67(8):820-828.

Liu W, Chang B-L, Li T, Sun J, Turner AR, Dimitrov L, Zhu Y, Sun J, Kim JW, Zheng SL, Xu J, et al. Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers. Genes Chromosomes Cancer. 2007;46(11):972-980.

Liu W, Chang B-L, Cramer S, Koty PP, Li T, Sun J, Turner AR, Von Hap-Herr C, Zheng SL, Xu J, et al. Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers. Clin Cancer Res. 2007;13(17):5028-5033.

Zheng SL, Sun J, Cheng Y, Li G, Hsu F-C, Zhu Y, Chang B-L, Liu W, Kim JW, Turner AR, Xu J, et al. Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst. 2007;99(20):1525-1533.

Loza MJ, McCall CE, Li L, Isaacs WB, Xu J, Chang B-L. Assembly of inflammation-related genes for pathway-focused genetic analysis. PLoS ONE. 2007;2(10):e1035.

Duggan D, Zheng SL, Dimitrov L, Cheng Y, Li G, Sun J, Chang B-L, Liu W, Kim JW, Bleecker ER, Meyers DA, Xu J, et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB21P. J Natl Cancer Inst. 2007;99(24):1836-1844.

Hsing AW, Sakoda LC, Chen J, Chokkalingam AP, Sesterhenn I, Gao Y-T, Xu J, Zheng SL. MSR1 variants and the risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China. Carcinogenesis. 2007;28(12):2530-2536.

Shahedi K, Lindstrom S, Zheng SL, Wiklund F, Adolfsson J, Sun J, Augustsson-Balter K, Chang B-L, Liu W, Xu J, et al. Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer. 2006;119(3):668-672.

Liu W, Chang B, Sauvageot J, Dimitrov L, Gielzak M, Li T, Yan G, Sun J, Sun J, Adams TS, Turner AR, Kim JW, Meyers DA, Zheng SL, Isaacs WB, Xu J. Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array. Genes Chromosomes Cancer. 2006;45(11):1018-1032.

Freedman BI, Hsu FC, Lohman K, Bowden DW, Leonchik L [sic] [Lenchik L], Langefeld CD, Xu J, Register Tc, Rich SS, Wagenknecht LE. The relationship between calcified atherosclerotic plaque and bone mineral density: the Diabetes Heart Study [abstract]. Atheroscler Suppl. 2006;7(3):14.

Zheng SL, Liu W, Dimitrov L, Sun J, Sun J, Chang B, Loza M, Turner AR, Bleecker ER, Meyers DA, Xu J, et al. A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS Study. Prostate. 2006;66(14):1556-1564.

Lindstrom S, Zheng SL, Wiklund F, Jonsson B-A, Adami H-O, Balter KA, Brookes AJ, Sun J, Chang B-L, Liu W, Li G, Xu J, et al. Systematic replication study of reported genetic associations in prostate cancer: strong support for genetic variation in the androgen pathway. Prostate. 2006;66(16):1729-1743.

Hedelin M, Chang ET, Wiklund F, Bellocco R, Klint A, Adolfsson J, Shahedi K, Xu J, Adami H-O, Gronberg H, Balter KA. Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int J Cancer. 2006;120(2):398-405.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2013-2014Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.